000			02223 a2200565 4500
005			20250514182415.0
264		0	_c20040408
008			200404s 0 0 eng d
022			_a0732-183X
024	7		_a10.1200/JCO.2004.10.046 _2doi
040			_aNLM _beng _cNLM
100	1		_aTedesco, K L
245	0	0	_aDocetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. _h[electronic resource]
260			_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cMar 2004
300			_a1071-7 p. _bdigital
500			_aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aDisease-Free Survival
650	0	4	_aDocetaxel
650	0	4	_aFemale
650	0	4	_aGene Expression Regulation, Neoplastic
650	0	4	_aHumans
650	0	4	_aIn Situ Hybridization, Fluorescence
650	0	4	_aMiddle Aged
650	0	4	_aReceptor, ErbB-2 _xantagonists & inhibitors
650	0	4	_aReceptor, ErbB-3 _xantagonists & inhibitors
650	0	4	_aSurvival Analysis
650	0	4	_aTaxoids _xadministration & dosage
650	0	4	_aTrastuzumab
650	0	4	_aUnited States
650	0	4	_aUp-Regulation
700	1		_aThor, A D
700	1		_aJohnson, D H
700	1		_aShyr, Y
700	1		_aBlum, K A
700	1		_aGoldstein, L J
700	1		_aGradishar, W J
700	1		_aNicholson, B P
700	1		_aMerkel, D E
700	1		_aMurrey, D
700	1		_aEdgerton, S
700	1		_aSledge, G W
773	0		_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 22 _gno. 6 _gp. 1071-7
856	4	0	_uhttps://doi.org/10.1200/JCO.2004.10.046 _zAvailable from publisher's website
999			_c14739966 _d14739966